Price is getting capped. The big order at 10.5c is probably one of our insto holders. If the options aren’t in the money at the end of 2023 they’ll need to be a raise soon after I’d imagine.
Yes the global market is bearish so who wants to put $s into a $20m MC biotech?
Early efficacy on the ACCENT trial is our catalyst for a rerate.
share price, page-5
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.5¢ |
Change
-0.005(3.85%) |
Mkt cap ! $34.27M | |||
| Open | High | Low | Value | Volume |
| 13.0¢ | 13.0¢ | 12.0¢ | $120.7K | 983.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 279677 | 12.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 16317 | 1 |
View Market Depth
| Last trade - 15.44pm 23/08/2024 (20 minute delay) ? |
| ATX (ASX) Chart |